AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01599598 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation
Description: Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will listen to PMR instruction by way of a mp3 player.
Study NCT01599598 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coherence Advantage
Description: Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will practice the techniques while using a biofeedback device to recognize when they enter psychophysiological coherence.
Study NCT03440801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synergy
Description: Biodegradable-polymer everolimus-eluting stent Synergy
Study NCT03440801 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synergy
Description: Biodegradable-polymer everolimus-eluting stent Synergy
Study NCT01562145 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Four mL venous blood samples were collected from all study participants after inclusion
Study NCT01902537 — intervention group
Intervention type: DRUG
Intervention: Prucalopride; observational study
Description: This is an observational study. Korean female participants with chronic constipation and having received treatment previously will be assessed for the health related QoL.
Study NCT03440801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xience
Description: Durable-polymer everolimus-eluting stent Xience
Study NCT03440801 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience
Description: Durable-polymer everolimus-eluting stent Xience
Study NCT01704508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Study NCT01704508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine
Study NCT00326001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gold tip catheter
Description: Radiofrquency ablation using gold tip catheter
Study NCT00326001 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Platinum-iridium tip catheter
Description: Radiofrequency ablation using platinum-iridium tip catheter
Study NCT03826459 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Locking Uterine Closure
Description: The first layer of the two-layer uterine closure will be sutured with a running \& non-locking technique. The second layer cannot be of a locking technique.
Study NCT03826459 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Locked Uterine Closure
Description: The first layer of the two-layer uterine closure will be sutured with a running \& locking technique. The second layer can be locking or non-locking.
Study NCT01504893 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protective one lung ventilation
Description: Low tidal volume, PEEP and alveolar recruitment maneuver
Study NCT03751826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incentivised network delivery of HIV-ST
Description: Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the first intervention arm will encourage females aged 18-24 to use the HIV-ST to test for HIV themselves and in their peers and friends. They will be counselled to receive sexual and reproductive health services, contraception and condoms, HIV confirmatory testing and linkage to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
Study NCT03751826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer navigator delivery of HIV-ST
Description: Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the second intervention arm will encourage females aged 18-24 to use the HIV-ST to test for HIV and then receive sexual and reproductive health services, contraception and condoms, HIV confirmatory testing and linkage to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
Study NCT03751826 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the standard of care arm encourage females aged 18-24 to test for HIV, receive sexual and reproductive health services, contraception and condoms, and link to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
Study NCT04692012 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FRESH CORNEAL MYOPIC LENTICULE IMPLANTATION
Description: VisuMax femtosecond laser performed flap-cut procedure with an energy cut index of 30 nJ (150nJ), spot and track spacing surface cut of 4.5 μm, side cut 2.0 μm were used to create an intrastromal pocket into the patient's cornea to receive the donor lenticule. The stromal pocket diameter was set 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness was set to 130 μm from corneal surface and a 4 mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision. Incision position changed according to the position of the highest K values. Current orientation was marked with a sterile skin marker. The lenticule was positioned around the marked center of the cone and flattened out from the surface using a blunt spatula.
Study NCT02931838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Study NCT03525457 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non Surgical Periodontal Therapy
Description: Non Surgical Periodontal Therapy in 2 to 3 sessions
Study NCT05671315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b Injection, Nucleos (t) ide Analogue
Description: 1.Peginterferon alfa-2b injection: 180μg, subcutaneously inject, once a week, from week 1 to Week 48.~2, NAs: Dose please follow the approved dosage, once daily, from the first day until when discontinuation is indicated.~NAs Discontinuation Criteria: A total course of treatment is recommended for at least 4 years, and discontinuation may be considered if HBV DNA is below the lower limit of detection, Alanine aminotransferase renormalization, and HBeAg serological conversion, and remain unchanged (test every 6 months) during a consolidation therapy for at least 3 years. However, a prolonged course of treatment may reduce relapse.
Study NCT05671315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nucleos(t)ide analogue
Description: NAs: Dose please follow the approved dosage, once daily, from the first day until when discontinuation is indicated.~NAs Discontinuation Criteria: A total course of treatment is recommended for at least 4 years, and discontinuation may be considered if HBV DNA is below the lower limit of detection, Alanine aminotransferase renormalization, and HBeAg serological conversion, and remain unchanged (test every 6 months) during a consolidation therapy for at least 3 years. However, a prolonged course of treatment may reduce relapse.
Study NCT01001728 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Imaging investigations (with radiation)
Study NCT02931838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for BMS-986165
Study NCT01526941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods
Study NCT01526941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods
Study NCT01027650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN208397 intravitreal injection
Description: AGN208397 intravitreal injection on Day 1.
Study NCT01027650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone intravitreal implant
Description: Dexamethasone 700 ug intravitreal implant on Day 1.
Study NCT03281629 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active TMS stimulation
Description: Multiple trains of active transcranial magnetic stimulation in a day, for multiple days.
Study NCT03281629 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS stimulation
Description: Multiple trains of sham transcranial magnetic stimulation in a day, for multiple days.
Study NCT03549338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym004
Description: Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.
Study NCT03549338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futuximab
Description: Futuximab is one of two mAb components that constitute Sym004.
Study NCT03549338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modotuximab
Description: Modotuximab is one of two mAb components that constitute Sym004.
Study NCT01251562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterile Compound C31510 for Injection
Description: During the treatment period, subjects in each initial dose level cohort will have a single 4-hour IV infusion of C31510 at the assigned dose level of their particular cohort, three times per week for 26 days (on Day 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26) followed by a 28-day follow up period that will be counted from the first dose given on Day 1. In the absence of unacceptable toxicity or disease progression during the treatment period, those subjects may receive similar 28-day repeat treatment cycles of 3 times per week for up to 1 year, at the discretion of the investigator.
Study NCT01109069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: Dose based on parent protocol
Study NCT02818413 — intervention group
Intervention type: OTHER
Intervention: Biospecimen collection and questionnaires
Description: Biospecimen collection and questionnaires
Study NCT03457766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU
Description: Ultrasound (Esaota MyLabSeven) imaging system using (SL2325) probe with (6-19 MHz) frequency
Study NCT02953613 — intervention group
Intervention type: DEVICE
Intervention: NIRS/IVUS
Description: Cardiac catheterization using infraredx
Study NCT03927911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXPAREL and Bupivacaine
Description: Drug: EXPAREL and Bupivacaine HCl 0.5%
Study NCT03927911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study NCT04589962 — intervention group
Intervention type: OTHER
Intervention: access axillary or brachial artery
Description: access to the axillary or brachial artery during Transcatheter Aortic Valve Implantation (TAVI), Fenestrated/Branched-Endovascular Aortic Repair (F/BEVAR), chimney-EVAR (Ch-EVAR) or visceral side branches stenting
Study NCT00562640 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Stem cell mobilization and harvest: Patients receive filgrastim (G-CSF) subcutaneously daily for five days. PBMC are collected by leukapheresis on the fifth day and then cryopreserved for subsequent reinfusion into the patient, in the event of prolonged cytopenia.
Study NCT00562640 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Autologous T-cell infusion with or without conditioning chemotherapy ( fludarabine treatment closed as of 12/01/2009): Approximately 4-6 weeks after T-cell sensitization, patients receive an infusion of autologous WT1-specific T cells over 5-10 minutes on day 0. Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2 and fludarabine phosphate IV over approximately 30 minutes on days -6 to -2. After a 48-hour rest period, patients receive autologous WT1-specific T cells. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after completion of therapy, may receive additional courses of autologous WT1-specific T cells every 14 days.
Study NCT00562640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2
Study NCT00562640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Obtained prior to adoptive therapy to quantitate baseline levels of WT1 reactive T cells, by quantitation of WT1 specific CTLp by LDA, T cells secreting IFNγ in response to peptide and, in HLA A0201+ patients, T cell binding WT1 peptide HLA A2 tetramers.
Study NCT02560493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergaming Condition
Description: Participants are encouraged to meet the MVPA goal of 60 minutes/day, which will be gradually achieved beginning with 10 minutes/day in Week 1 and reaching 60 minutes/day in Week 6. Three hours each week will be devoted to exergame play, following prescribed exergame routines.
Study NCT01952704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Study NCT01952704 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Non-aerobic stretching sessions will be conducted 3x/week for 30 minutes over 12 weeks.
Study NCT02658968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betalutin
Description: Dose finding study, starting on 10 MBq/kg b.w. Betalutin® (lutetium (177Lu)-lilotomab satetraxetan), single injection with lilotomab pre-dosing.
Study NCT01354613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: IV administration at the initial study visit (all groups) and at the final study visit for the drug intervention arm (HFpEF group only). Administration of low-dose dobutamine at 5mcg/kg/min and 10mcg/kg/min for periods of approximately 30minutes/dose for purposes of performing a low-dose stress exam on the heart.
Study NCT01354613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dobutamine
Description: IV administration at the initial study visit (all groups) and at the final study visit for the drug intervention arm (HFpEF group only). Administration of low-dose dobutamine at 5mcg/kg/min and 10mcg/kg/min for periods of approximately 30minutes/dose for purposes of performing a low-dose stress exam on the heart.
Study NCT01163396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT01163396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT01163396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT01163396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/leucovorin
Study NCT04001439 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Experimental drug
Description: All patients will recive 30 microbiota capsules intake preceded by bowel lavage by 4 liters macrogol solution. the capsules are developed by the services of JC Lagier.
Study NCT00994825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Study NCT00994825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Soluvit ATC BO5XC (a mixture of vitamins with a yellow colour that is indistinguishable from the study drug Levosimendan) half ampul in 100 ml of glucose 5%
Study NCT00921115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant IM on day 14 and on day 28 followed by day 28 of all subsequent cycles thereafter. Treatment will be continued for a total of 4 cycles.
Study NCT00921115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrazole
Description: Anastrazole, 1mg by mouth every day of all 28 day cycles and continued for a total of 4 cycles
Study NCT02025634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Acetaminophen
Description: Participants randomized to intravenous acetaminophen (Ofirmev) will receive an infusion of Ofirmev in 100 ml of 0.9 NS according to manufacturer's recommendations related to subject's weight.
Study NCT02025634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% Normal Saline infusion)
Description: Infusion of 100 ml of 0.9% NS
Study NCT01218217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: SQ109 150 mg tablet
Study NCT01218217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: Rifampicin 150 mg capsules
Study NCT01218217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin 150 mg capsules
Study NCT04593368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMT
Description: oral dosing of fecal microbiome from allogeneic donor, 0.5-2 g/kg of recipients weight
Study NCT03023306 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Antiemetics perioperatively
Description: Preemptive group ondansetron 4 mg will be administered 1h before surgery Intraoperative group Ondansetron 4 mg will be administered intraoperatively
Study NCT03023306 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antiemetics perioperatively
Description: Preemptive group ondansetron 4 mg will be administered 1h before surgery Intraoperative group Ondansetron 4 mg will be administered intraoperatively
Study NCT02270658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Study NCT02270658 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CPAP
Study NCT03929354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Factors Modification Programme
Description: 12-week supervised risk factor modification programme derived from the EuroAction Study standards.
Study NCT03929354 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Patients advised to adjust lifestyle without the support of the structured supervised programme.
Study NCT01198782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops)
Description: Patients will dose 4 times daily for 4 months.
Study NCT04169646 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multi-component intervention
Description: Participants' workstation ergonomics will be assessed using an observation-based ergonomics assessment checklist for office-workers adapted to Swiss guidelines. Based on the initial assessment, best practice ergonomics will be applied individually using existing infrastructure. Participants will attend health promotion information group workshops for approximately one hour per week for 12 weeks. it. Participants will receive an individual progressive exercise programme aimed at conditioning the muscles of the neck and shoulder girdle. The exercises will be performed in groups (maximum of ten per group) at the workplace in a dedicated room, for approximately one hour (3x20 minutes) per week; once per week supervised by a physiotherapist, a human movement scientist, or a health scientist, and twice per week individually. Workshop session attendance will be recorded as an indication of adherence to health promotion. Adherence to neck exercises will be recorded with the Physitrack® app.
Study NCT04169646 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No intervention takes place during the control phase.
Study NCT03599518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1205c
Description: DS-1205c 200 mg capsule for oral administration
Study NCT03599518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250 mg tablet for oral administration
Study NCT03884153 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRP apheresis
Description: selective CRP apheresis by use of the PentraSorb-CRP
Study NCT02790840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 20 mg oral capsules administered once daily for 10 days